Almirall
Ronda General Mitre, 151
Barcelona
Tel: 93-291-30-00
100 articles about Almirall
-
Almirall will have exclusive global rights to develop and commercialize the anti-IL-21 monoclonal antibody NN-8828 in several fields, including immune inflammatory dermatological indications.
-
Almirall to Participate in the 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Almirall to Participate in the 41st Annual J.P. Morgan Healthcare Conference.
-
Almirall PROSES study demonstrates appropriate acne treatment decreases the burden of impact on acne sufferers’ social and emotional wellbeing
10/21/2022
Almirall, LLC, a global biopharmaceutical company focused on skin health, is excited to announce the release of its privately funded PROSES study at this year’s Fall Clinical Dermatology Conference® in Las Vegas, Nevada, October 20-23, 2022.
-
Almirall's Klisyri® (tirbanibulin) receives strong recommendation in American Academy of Dermatology AK guideline update
8/18/2022
Almirall, LLC, a global biopharmaceutical company focused on skin health, announced its microtubule inhibitor ointment, KLISYRI® (tirbanibulin), a topical field treatment for actinic keratosis (AK) of the face and scalp, received a strong recommendation designation in the AAD's American Academy of Dermatology's Focused Update to the Guidelines of Care for the Management of Actinic Keratosis.
-
Almirall achieves Core Net Sales growth of 5.1% to 436.6 MM Euros in H1
7/25/2022
Almirall, S.A., the global biopharmaceutical company based in Barcelona, announced its H1 2022 financial results.
-
The Phase III ADvocate 1 and 2 studies on lebrikizumab showed that eight out of 10 patients with atopic dermatitis maintained skin clearance in the 12 months they had been under treatment.
-
Germany-based Evotec AG forged its third partnership in May, a deal with Spain’s Almirall S.A. to develop new therapeutics for severe diseases of the skin.
-
Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.
-
Eli Lilly has announced the success of its clinical trial on lebrikizumab as a treatment for people diagnosed with moderate to severe atopic dermatitis.
-
Almirall receives positive CHMP opinion for Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis
5/21/2021
Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis (AK) of the face or scalp and it acts through a selective antiproliferative mechanism of action
-
Almirall announces New England Journal of Medicine publication of Phase III data demonstrating efficacy and safety of Klisyri® (tirbanibulin)
2/11/2021
Almirall announced today that the New England Journal of Medicine (NEJM) has published the results from the pivotal Phase III trials of Klisyri® (tirbanibulin) ointment for actinic keratosis.
-
Almirall announces Gianfranco Nazzi as new CEO
2/3/2021
Gianfranco Nazzi brings broad international experience from a distinguished career in Pharma Mr. Nazzi will join Almirall as Chief Executive Officer on May 1, 2021
-
Almirall launches its second innovation initiative for dermatology-focused digital health start-ups
10/16/2020
Almirall, S.A. (ALM ) has launched its second innovation challenge open to worldwide startups who can disrupt the future of digital health. Start-ups can apply between now and October 31 at almiralldigitalgarden.com for a chance to participate in the nine-month accelerator program Digital Garden , powered by Almirall
-
Almirall: Sustained performance of key growth drivers and excellent progress on pipeline in H1 despite negative impact of COVID-19
7/27/2020
Financial highlights
-
Almirall Announces FDA Approval Of Updated Label For Seysara® (Sarecycline) Tablets
6/18/2020
Almirall LLC today announced that the FDA approved an important update to the Seysara® label stating that P. acnes strains displayed a low propensity for the development of resistance to sarecycline
-
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
1/9/2020
WuXi Biologics announced the signing of a strategic collaboration agreement enabling Almirall to leverage the proprietary WuXiBody™ platform to develop bispecific antibodies for dermatological diseases.
-
Bioniz Therapeutics enters into an option agreement for acquisition by Almirall of its lead clinical candidate BNZ-1 in development for immuno-dermatologic and onco-dermatologic diseases
1/9/2020
Bioniz Therapeutics, Inc. announced the execution of an option agreement for acquisition by Almirall including its lead candidate, BNZ-1.
-
Iktos and Almirall Announce Research Collaboration in Artificial Intelligence for New Drug Design
12/12/2019
Generative modelling artificial intelligence (AI) technology will be used to optimise advanced compounds, to speed up the identification of promising drug candidates for an undisclosed Almirall drug discovery program.
-
Almirall LLC Announces The Publication Of Long-Term Safety Data For The Use Of Seysara® (Sarecycline) Tablets In Patients 9 Years Of Age And Older
12/6/2019
Almirall LLC today announced the publication of long-term safety data from a 40 week, Phase 3 open-label extension study of Seysara® in patients 9 years of age and older. Seysara® is a novel tetracycline-derived oral antibiotic developed specifically for the treatment of acne and was approved by the FDA in October of 2018
-
Athenex Announces Progress Update from Partner Almirall on Tirbanibulin Ointment
10/28/2019
Athenex, Inc. announced a progress update from partner Almirall on tirbanibulin ointment for the treatment of actinic keratosis